PMC

Proportions of patients with sustained virologic response (SVR) according to IL28B genotype and race/ethnicity. Adapted from Ge et al.

On-treatment viral kinetics and definitions of response to triple-drug treatment (peginterferon alfa ribavirin, and a direct-acting antiviral [DAA]) for hepatitis C virus (HCV). Adapted from Yee et al.

Stopping (futility) rules for triple-drug therapy including boceprevir (BOC; top) or telaprevir (TVR; bottom) in treatment-naive patients. HCV indicates hepatitis C virus; PIFN/R, peginterferon and ribavirin. Adapted from Barritt et al.

Survival according to sustained virologic response (SVR), relapse, nonresponse, or no treatment in hepatitis C virus (HCV)/HIV coinfected patients at Johns Hopkins HIV Clinic. Adapted from Limketkai et al.

Design and outcomes of phase II trials SPRINT (Serine Protease Inhibitor Therapy) and PROVE (Protease Inhibitor for Viral Evaluation) studies of boceprevir (BOC) and telaprevir (TVR). PIFN indicates peginterferon alfa; R, ribavirin; SOC, standard of care (peginterferon alfa and ribavirin); SVR, sustained virologic response. Compiled from McHutchison et al, Hezode et al, and Kwo et al.